ML-T7 (10-50 mg/kg; Intraperitoneal injection; every 2 days, 10 times) inhibits the growth of tumor and prolongs survival of HCC mice, without adverse effects on mice body weight[1].
ML-T7 (20 mg/kg; Intraperitoneal injection; every 2 days, 10 times) synergizes with Nivolumab (HY-P9903A) to improve the antitumor efficacy of Nivolumab (HY-P9903A) antibodies, and effectively improves HCC mice survival[1].
ML-T7 (50 mg/kg, Intraperitoneal injection; every 2 days for 3 weeks)shows a good safety profile in mice[1].
| Animal Model: | 10-week-old mice with spontaneous orthotopic HCC[1] |
| Dosage: | 10-50 mg/kg |
| Administration: | Intraperitoneal injection (i.p.), every 2 days, 10 times |
| Result: | Increased CD8+ T cells in both tumor and spleen.
Inhibited T cell exhaustion.
Promoted the function of CTLs, NK cells, and DCs. |
| Animal Model: | 10-week-old mice with orthotopic Akt/c-Myc HCC[1] |
| Dosage: | 20 mg/kg |
| Administration: | Intraperitoneal injection (i.p.), every 2 days, 10 times |
| Result: | Indicated stronger antituomr activity when treated with ML-T7 and Nivolumab (HY-P9903A).
Rejuvenated NK cells by the combination therapy.
Inhibited the accumulation of MDSCs and Tregs. |